The role of exercise testing in the management of pulmonary arterial hypertension

Seminars in Respiratory and Critical Care Medicine

Volumn 26, Issue 4, 2005, Pages 379-384

  Oudiz, Ronald J ^a,b,c  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

6 minute walk test; Cardiopulmonary exercise test; Exercise testing

Indexed keywords

BOSENTAN; PROSTACYCLIN;

CARDIOPULMONARY HEMODYNAMICS; CLINICAL PRACTICE; DISEASE EXACERBATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; EVALUATION; EXERCISE TEST; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SURVIVAL; TREATMENT OUTCOME; VALIDATION PROCESS; WALKING;

ECHOCARDIOGRAPHY; EXERCISE TEST; EXERCISE TOLERANCE; HUMANS; HYPERTENSION, PULMONARY;

EID: 24644507097     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-916152     Document Type: Review

References (35)

1. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302
2. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346: 896-903
3. Yetman AT, Taylor AL, Doran A, Ivy DD. Utility of cardiopulmonary stress testing in assessing disease severity in children with pulmonary arterial hypertension. Am J Cardiol 2005;95:697-699
4. Wax D, Garofano R, Barst RJ. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension. Chest 1999;116:914-920
5. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985;132:919-923
6. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-1123
7. Galiè N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-1502
8. Langleben D, Christman BW, Barst RJ, et al. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J 2002;143:E4
9. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347: 322-329
10. Simonneau G, Barst RJ, Galiè N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-804
11. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119-2125
12. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377-381
13. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85:751-758
14. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-788
15. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487-492
16. Paciocco G, Martinez FJ, Bossone E, Pielsticker E, Gillespie B, Rubenfire M. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 2001;17:647-652
17. Paciocco G, Martinez FJ, Bossone E, et al. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 2001;17:647-652
18. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126(suppl 1):14S-34S
19. Oudiz RJ, Sun XG. Abnormalities in exercise gas exchange in primary pulmonary hypertension. In: Wasserman K, ed. Cardiopulmonary Exercise Testing and Cardiovascular Health. Armonk, NY: Futura; 2002:179-190
20. Beaver WL, Wasserman K, Whipp BJ. A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol 1986;60:2020-2027
21. Sun X-G, Oudiz RJ, Hansen JE, Wasserman K. Exercise pathophysiology in primary pulmonary hypertension. Circulation 2001;104:429-435
22. Wasserman K, Hansen JE, Sue DY, Casaburi R, Whipp BJ, eds. Principles of Exercise Testing and Interpretation. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2004
23. Markowitz DH, Systrom DM. Diagnosis of pulmonary vascular limit to exercise by cardiopulmonary exercise testing. J Heart Lung Transplant 2004;23:88-95
24. Deboeck G, Niset G, Lamotte M, Vachiery J-L, Naeije R. Exercise testing in pulmonary arterial hypertension and in chronic heart failure. Eur Respir J 2004;23:747-751
25. Wensel R, Opitz CF, Anker SD, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002;106: 319-324
26. Janicki JS, Gupta S, Ferris ST, et al. Long-term reproducibility of respiratory gas exchange measurements during exercise in patients with stable cardiac failure. Chest 1990; 97:12-17
27. Hansen JE, Sun XG, Yasunobu Y, et al. Reproducibility of cardiopulmonary exercise measurements in patients with pulmonary arterial hypertension. Chest 2004;126:816-824
28. Porszasz J, Casaburi R, Somfay A, Woodhouse LJ, Whipp BJ. A treadmill ramp protocol using simultaneous changes in speed and grade. Med Sci Sports Exerc 2003;35:1596-1603
29. Himelman RB, Stulbarg M, Kircher B, et al. Noninvasive evaluation of pulmonary artery pressure during exercise by saline-enhanced Doppler echocardiography in chronic pulmonary disease. Circulation 1989;79:863-871
30. Oelberg DA, Marcotte F, Kreisman H, Wolkove N, Langleben D, Small D. Evaluation of right ventricular systolic pressure during incremental exercise by Doppler echocardiography in adults with atrial septal defect. Chest 1998;113: 1459-1465
31. Vachiery JL, Brimioulle S, Crasset V, Naeije R. False-positive diagnosis of pulmonary hypertension by Doppler echocardiography. Eur Respir J 1998;12:1476-1478
32. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004;43:1149-1153
33. 2 as a measure of ventilatory efficiency and exercise limitation in patients with primary pulmonary hypertension. Chest 2005;127:1637-1646
34. Costanzo MR, Augustine S, Bourge R, et al. Selection and treatment of candidates for heart transplantation: a statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation 1995;92:3593-3612
35. Stevenson LW. Role of exercise testing in the evaluation of candidates for cardiac transplantation. In: Wasserman K, ed. Exercise Gas Exchange in Heart Disease. Armonk, NY: Futura; 1996:271